Clopidogrel

Clopidogrel is a platelet aggregation inhibitor, a type of antithrombotic drug commonly called a blood thinner, belonging to the thienopyridine family ^[1]. Rather than acting on the clotting proteins targeted by drugs such as warfarin, it works on platelets, the small cell fragments that clump together to start a clot, reducing their tendency to stick to one another ^[1][4]. Because it is a prodrug, clopidogrel itself is inactive when swallowed and must be chemically transformed in the liver before it can act ^[4].

The molecule was patented in 1982 and was developed by the French pharmaceutical company Sanofi; it received approval in the United States in 1997 and went on to become one of the best-selling drugs in the world under the brand name Plavix, also sold as Iscover ^[1]. After the expiry of its patents it has become widely available as a low-cost generic and is included on the World Health Organization Model List of Essential Medicines ^[1].

Clopidogrel is prescribed to lower the risk of heart attack, stroke and death from cardiovascular causes in people who have atherosclerotic disease, including those who have already had a heart attack or ischaemic stroke or who have peripheral artery disease ^[1]. It is a cornerstone of treatment for acute coronary syndromes and is routinely combined with aspirin as dual antiplatelet therapy after a coronary stent is placed, a regimen that helps keep the stent from clotting ^[1][5]. For patients who cannot tolerate aspirin, clopidogrel is often used as an alternative ^[1].

A distinctive feature of clopidogrel is that its effectiveness depends on how well an individual's liver activates it ^[4][5]. The conversion to the active metabolite relies heavily on the enzyme CYP2C19, and a substantial minority of people carry reduced-function versions of the CYP2C19 gene ^[2][5]. Studies have shown that these poor metabolisers generate less active drug, achieve weaker platelet inhibition and face a higher rate of adverse cardiovascular events, including stent thrombosis, than people with normal enzyme activity ^[2][3][5]. This has prompted interest in genetic testing to guide therapy, although the routine use of such testing remains a subject of debate ^[5].

As with all drugs that reduce clotting, the main risk of clopidogrel is bleeding, ranging from easy bruising and nosebleeds to more serious gastrointestinal or other haemorrhage, and the risk rises when it is combined with aspirin ^[1]. Other reported effects include indigestion, diarrhoea and rash, and a rare but serious blood disorder called thrombotic thrombocytopenic purpura has been described ^[1]. It is a prescription-only medicine taken as oral tablets ^[1].

Clopidogrel is prescription only. Its main risk is bleeding, from easy bruising and nosebleeds to more serious gastrointestinal or intracranial bleeds, and this rises when it is combined with aspirin, anticoagulants, or NSAIDs. It is usually paused before surgery. Because it needs CYP2C19 to work, people who are poor metabolizers of that enzyme get less protection, and strong CYP2C19 inhibitors such as the acid-reducer omeprazole can blunt its effect, so an alternative acid reducer is often chosen. Other effects include rash and, rarely, a serious clotting disorder called TTP. It is used cautiously in active bleeding and severe liver disease.

Clopidogrel is a prodrug that needs CYP2C19 to generate its active thiol metabolite, so anything blocking that enzyme blunts the antiplatelet effect. Omeprazole and esomeprazole are the documented offenders, lowering active metabolite concentrations and measured platelet inhibition; pantoprazole and most other proton pump inhibitors interfere far less. The same logic applies to CYP2C19 poor metabolizers, in whom the drug simply works less well.

Bleeding risk is additive with anticoagulants, aspirin and NSAIDs, and with SSRIs and SNRIs, which impair platelet serotonin uptake.

Clopidogrel is itself a potent CYP2C8 inhibitor and raises repaglinide exposure several-fold, with hypoglycemia the consequence.

Morphine and other opioids slow gastric emptying and delay clopidogrel absorption, which matters specifically in acute coronary syndromes where speed of onset is the entire point.

Checking a whole stack? Run it through interactions + stacks.

Clopidogrel was discovered by the French pharmaceutical company Sanofi as a successor to the earlier thienopyridine ticlopidine, which suffered from serious blood-cell side effects. Developed through the late 1980s and 1990s, clopidogrel offered comparable antiplatelet action with a much better safety profile, and the large CAPRIE trial published in 1996 established its benefit against atherothrombotic events.

It received United States approval in 1997 and was marketed as Plavix by Sanofi and Bristol-Myers Squibb, going on to become one of the best-selling medicines in the world. It is a prodrug that the liver must convert to its active form, chiefly through the CYP2C19 enzyme, and it earned a place on the World Health Organization list of essential medicines. Recognition that reduced-function variants of CYP2C19 blunt the drug's effect later prompted a regulatory boxed warning highlighting this pharmacogenetic vulnerability.

Clopidogrel is regarded as a cornerstone antiplatelet drug and a workhorse of cardiovascular medicine, underpinned by one of the largest evidence bases of any oral antiplatelet agent. It is valued as the standard partner to aspirin after coronary stent placement and in acute coronary syndromes, and its availability as an inexpensive generic has made it broadly accessible. Its reputation is honest about a key limitation; because it must be activated by the liver, patients who carry poorly functioning forms of the CYP2C19 enzyme derive less protection, which has driven interest in genotype-guided therapy. In some acute settings it has been partly supplanted by newer agents such as ticagrelor and prasugrel that do not depend on this activation step. Even so, it remains a trusted, well-characterized foundation of antiplatelet treatment.